TCGA-55-A490-01A-11R-A466-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.470
- MYOGENESIS+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- APICAL_JUNCTION+0.280
- COAGULATION+0.260
- APICAL_SURFACE+0.240
- KRAS_SIGNALING_DN+0.230
- MITOTIC_SPINDLE+0.170
- ESTROGEN_RESPONSE_EARLY+0.160
- WNT_BETA_CATENIN_SIGNALING+0.160
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- OXIDATIVE_PHOSPHORYLATION-0.370
- INTERFERON_GAMMA_RESPONSE-0.360
- MTORC1_SIGNALING-0.300
- MYC_TARGETS_V1-0.270
- FATTY_ACID_METABOLISM-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
- BILE_ACID_METABOLISM-0.240
- E2F_TARGETS-0.240
- PROTEIN_SECRETION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a2a777ef-9294-4acf-b489-27bc17272b5e | — | — | 0.827 |
| 2 | TCGA-55-8614-01A-11R-2403-07 | — | cohortSQ1 | 0.820 |
| 3 | SRR6013528 | — | cohortSQ1 | 0.818 |
| 4 | TCGA-MP-A4TK-01A-11R-A24X-07 | — | cohortA1 | 0.808 |
| 5 | SRR8613753 | — | C | 0.803 |
| 6 | TCGA-CR-6488-01A-12R-2081-07 | — | — | 0.798 |
| 7 | TCGA-CN-6022-01A-21R-1686-07 | — | — | 0.791 |
| 8 | f825534d-5882-4efe-a32e-af56741854f6 | — | — | 0.789 |
| 9 | TCGA-CN-6989-01A-11R-1915-07 | — | — | 0.787 |
| 10 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.470 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| COMPLEMENT | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.030 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.020 | Inavolisib | — uncovered |